Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis

Adriana T Lopez; Joel Shugar; Mark Lebwohl

doi:10.25251/2.5.7

Adriana T Lopez

Columbia University Vagelos College of Physicians & Surgeons

Joel Shugar

Icahn School of Medicine at Mount Sinai, Department of Otolaryngology

Mark Lebwohl

Icahn School of Medicine at Mount Sinai, Department of Dermatology

Keywords

acquired ichthyosis, ichthyoses, gemcitabine, nab-paclitaxel

Abstract

The ichthyoses are a diverse group of cutaneous disorders characterized by abnormalities in cornification. The majority of ichthyoses are inherited with childhood presentation and new onset ichthyosis in adulthood warrants further medical evaluation. Though most well recognized for its association with Hodgkin’s disease, acquired ichthyosis (AI) has been linked to a number of inflammatory, autoimmune, and endocrine processes. However, drug induced AI is exceedingly rare and remains a poorly understood entity. Here we report the case of man with who developed AI while receiving nab-paclitaxel plus gemcitabine for treatment of pancreatic adenocarcinoma and review the literature.

References

1. Kim BE, Howell MD, Guttman-Yassky E, et al. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin barrier. J Invest Dermatol. 2011;131(6):1272-1279.

2. Patel N, Spencer LA, English JC, III, Zirwas MJ. Acquired ichthyosis. Journal of the American Academy of Dermatology. 2006;55(4):647-656.

3. London RD, Lebwohl M. Acquired ichthyosis and hyperparathyroidism. Journal of the American Academy of Dermatology. 1989;21(4 Pt 1):801-802.

4. DYKES PJ, MARKS R. Acquired ichthyosis: multiple causes for an acquired generalized disturbance in desquamation. British Journal of Dermatology. 1977;97(3):327-334.

5. Yokote R, Iwatsuki K, Hashizume H, Takigawa M. Lymphomatoid papulosis associated with acquired ichthyosis. Journal of the American Academy of Dermatology. 1994;30(5):889-892.

6. Aram H. Acquired ichthyosis and related conditions. Int J Dermatol. 1984;23(7):458-461.

7. Chiewchanvit S, Noppakun K, Kanchanarattanakorn K. Mucocutaneous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2004;87(5):508-514.

8. Alloo A, Sheu J, Butrynski JE, et al. Ponatinib‐induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities. British Journal of Dermatology. 2015;173(2):574-577.

9. Mittal A, Leventhal JS. Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon. JAAD Case Reports. 2017;3(3):190-195.

10. Curtis S, Hong S, Gucalp R, Calvo M. Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature. American journal of therapeutics. 2016;23(1):e321-323.

11. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol. 1992;52(1):119-121.

12. Dima SO, Tanase C, Albulescu R, et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012;41(7):1001-1007.

Full Article PDF

Published

Sep 7, 2018

DOI https://doi.org/10.25251/2.5.7

How to Cite

Lopez, A. T., Shugar, J., & Lebwohl, M. (2018). Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis. SKIN The Journal of Cutaneous Medicine, 2(5). https://doi.org/10.25251/2.5.7

Issue

Vol. 2 No. 5 (2018)

Section

Brief Articles

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)